VTVT
vTv TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The supported bull case is narrow but real: cadisegliatin remains a late-stage asset with Breakthrough Therapy designation, CATT1 enrollment is guided for 3Q 2026, and company filings indicate financing plus the Newsoara payment should fund operations well past the expected topline window [#10-K-2026-03-10].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
CATT1 enrollment or follow-up could slip, delaying the main value inflection beyond management's 3Q 2026 enrollment expectation [#10-K-2026-03-10].
Momentum
22
Value
41
Sentiment
43
Setup hits (3d)
— · Net —
AI TargetsBase $31.00 · Bull $48.00 · Bear $18.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net —
Target $58.17
Why
Momentum22 · Δ7d -28.1
Value41 · Δ7d -0.1
Sentiment43 · Δ7d -1.0
So what
Weak posture. Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
22
26% active weight
Current posture
7d trendSoftening
Δ7d
-28.1
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
43
34% active weight
Current posture
7d trendFlat
Δ7d
-1.0
Δ21d
-
Why this grade
Composite grade F. Momentum 22.0 / Value 41.1 / Sentiment 43.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$129.51M
Beta
0.50
Shares Out
3.94M
P/E (TTM) · Derived
-10.3
P/S (TTM)
9817.85
P/FCF (TTM) · Derived
-22.02
Rev YoY
-100.0%
EPS YoY
-313.2%
Gross Margin
+100.0%
Op Margin
-175382.4%
Net Debt
-$88.93M
Current Ratio
14.36
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology